Cited by 762Systemic Lupus Erythematosus ResearchSystemic Sclerosis and Related DiseasesClinical practice guidelines implementation

The DOI matches its Crossref record; 159 of the 164 references it cites were found in a registry or an index.

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

Open access

Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Gordon, C, Boumpas, D T·2008·Annals of the Rheumatic Diseases

DOI 10.1136/ard.2007.070367

Open this paper in CoChat — free account

Abstract

Objective Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. We sought to develop evidence-based recommendations addressing the major issues in the management of SLE. Methods The EULAR Task Force on SLE comprised 19 specialists and a clinical epidemiologist. Key questions for the management of SLE were compiled using the Delphi technique. A systematic search of PubMed and Cochrane Library Reports was performed using McMaster/Hedges clinical queries' strategies for questions related to the diagnosis, prognosis, monitoring and treatment of SLE. For neuropsychiatric, pregnancy and antiphospholipid syndrome questions, the search was conducted using an array of relevant terms. Evidence was categorised based on sample size and type of design, and the categories of available evidence were identified for each recommendation. The strength of recommendation was assessed based on the category of available evidence, and agreement on the statements was measured across the 19 specialists. Results Twelve questions were generated regarding the prognosis, diagnosis, monitoring and treatment of SLE, including neuropsychiatric SLE, pregnancy, the antiphospholipid syndrome and lupus nephritis. The evidence to support each proposition was evaluated and scored. After discussion and votes, the final recommendations were presented using brief statements. The average agreement among experts was 8.8 out of 10. Conclusion Recommendations for the management of SLE were developed using an evidence-based approach followed by expert consensus with high level of agreement among the experts.

Integrity signals

Registry

Crossref · 10.1136/ard.2007.070367

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citation
Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric Transplant
Wolfe, R. A., Ashby, V. B., Milford, E. L., OJO, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,370
Systemic Lupus Erythematosus
Tsokos, G. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Competing interests: none declared.
Hirsch, L. (2006) · Cited by 1,396
Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., et al. (2003) · Medicine · doi:10.1097/01.md.0000091181.93122.55 · Cited by 1,377
Therapy of Lupus Nephritis
Austin, H. A., Klippel, J. H., Balow, J. E., LeRICHE, N. G. H., Steinberg, A. D., Plötz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,189
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri, M., Kim, M., KALUNIAN, K. C., Grossman, J., Hahn, B. H., Sammaritano, L. R., Lockshin, M. D., Merrill, J. T., Belmont, M. H., Askanase, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051135 · Cited by 1,166
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ginzler, E. M., Dooley, M. A., Aranow, C. B., Kim, M., Buyon, J. P., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043731 · Cited by 1,122
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F., Tang, C. S.-O., Wong, R. W. S., Fang, G. X., Ji, Y., Lau, C. S., Wong, A. K., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 949

Show all 164 references

Research works printed but not linked: 1

2001, AGREE Instrument., The AGREE collaboration

Sorted by citations

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Navarra, S., Guzmán, R., Gallacher, A., Hall, S., Levy, R. A., Jimenez, R., Li, E. K., Thomas, M., Kim, H., Leon, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,078
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Self-citation
Systemic lupus erythematosus
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz‐Irastorza, G., & Hughes, G. R. V. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,480
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S., Boletis, J., Bruce, I. N., Cervera, R., Doria, A., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224762 · Cited by 1,243
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Bertsias, G. K., Tektonidou, M. G., Amoura, Z., Aringer, M., Bajema, I. M., Berden, J. H. M., Boletis, J., Cervera, R., Dörner, T., Doria, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201940 · Cited by 1,017
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
Update οn the diagnosis and management of systemic lupus erythematosus
Fanouriakis, A., Tziolos, N., Bertsias, G. K., & Boumpas, D. T. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218272 · Cited by 776
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task Force of the EULAR standing Committee for clinical Affairs
Bertsias, G. K., Ioannidis, J. P. A., Aringer, M., Bollen, E., Bombardieri, S., Bruce, I. N., Cervera, R., Dalakas, M., Doria, A., Hanly, J. G., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.130476 · Cited by 742
EULAR recommendations for the management of Behçet disease
Hatemi, G., Silman, A. J., Bang, D., Bodaghi, B., Chamberlain, A. M., Gül, A., Houman, M. H., Kötter, I., Olivieri, I., Salvarani, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.080432 · Cited by 705
Novel paradigms in systemic lupus erythematosus
Dörner, T., & Furie, R. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30546-x · Cited by 573
EFNS guidelines on diagnosis and management of neuromyelitis optica
Sellner, J., Boggild, M., Clanet, M., Hintzen, R. Q., Illés, Z., Montalbán, X., Pasquier, R. D., Polman, C. H., Sørensen, P. S., & Hemmer, B. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03066.x · Cited by 460
Methods of Formal Consensus in Classification/Diagnostic Criteria and Guideline Development
Nair, R., Aggarwal, R., & Khanna, D. (2011) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2010.12.001 · Cited by 441
Antiphospholipid syndrome
Schreiber, K. I., Sciascia, S., de Groot, P. G., Devreese, K. M. J., Jacobsen, S., Ruiz‐Irastorza, G., Salmon, J. E., Shoenfeld, Y., Shovman, O., & Hunt, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.103 · Cited by 445
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
van Vollenhoven, R., Petri, M., Cervera, R., Roth, D. A., Ji, B., Kleoudis, C. S., Zhong, Z. J., & Freimuth, W. W. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200937 · Cited by 411
Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature
Chatre, C., Roubille, F., Vernhet, H., Jørgensen, C., & Pers, Y. (2018) · Drug Safety · doi:10.1007/s40264-018-0689-4 · Cited by 398
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
Mosca, M., Tani, C., Aringer, M., Bombardieri, S., Boumpas, D., Brey, R. L., Cervera, R., Doria, A., Jayne, D. R. W., Khamashta, M. A., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.117200 · Cited by 382
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
Gordon, C., Amissah-Arthur, M.-B., Gayed, M., Brown, S., Bruce, I. N., D’Cruz, D. P., Empson, B., Griffiths, B., Jayne, D. R. W., Khamashta, M. A., et al. (2017) · Rheumatology · doi:10.1093/rheumatology/kex286 · Cited by 371
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies
Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24232 · Cited by 356
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
van Vollenhoven, R., Hahn, B. H., Tsokos, G. C., Wagner, C. L., Lipsky, P. E., Touma, Z., Werth, V. P., Gordon, R. M., Zhou, B., Hsu, B. L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32167-6 · Cited by 329
Physical activity and autoimmune diseases: Get moving and manage the disease
Sharif, Κ., Watad, ‬., Bragazzi, N. L., Lichtbroun, M., Amital, H., & Shoenfeld, Y. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.010 · Cited by 342
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Zhang, F., Bae, S., Bass, D., Chu, M., Egginton, S., Gordon, D., Roth, D. A., Zheng, J., & Tanaka, Y. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211631 · Cited by 306
Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases
Ramos‐Casals, M., Soto, M., Cuadrado, M., & Khamashta, M. A. (2009) · Lupus · doi:10.1177/0961203309106174 · Cited by 308
Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations
Bertsias, G. K., & Boumpas, D. T. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.62 · Cited by 283
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts
Díaz‐Lagares, C., Croca, S. C., Sangle, S. R., Vital, E. M. J., Catapano, F., Martínez-Berriotxoa, A., Hernández, F. J. G., Callejas-Rubio, J. L., Rascón, J., D’Cruz, D. P., et al. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.10.009 · Cited by 246
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus
Merrill, J. T., Wallace, D. J., Wax, S. D., Kao, A. H., Fraser, P. A., Chang, P., Isenberg, D. A., & on behalf of the ADDRESS II Investigators (2017) · Arthritis & Rheumatology · doi:10.1002/art.40360 · Cited by 246
Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study
Petri, M., Wallace, D. J., Spindler, A. J., Chindalore, V. L., KALUNIAN, K. C., Mysler, E., Neuwelt, C. M., Robbie, G. J., White, W. I., Higgs, B. W., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37824 · Cited by 238
Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives
Magro‐Checa, C., Zirkzee, E. J. M., Huizinga, T. W. J., & Steup‐Beekman, G. M. (2016) · Drugs · doi:10.1007/s40265-015-0534-3 · Cited by 244
The Diagnosis and Treatment of Systemic Lupus Erythematosus
Kuhn, A., Bonsmann, G., Anders, H., Herzer, P., Tenbrock, K., & Schneider, M. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0423 · Cited by 255
Lupus nephritis: A critical review
Borchers, A. T., Leibushor, N., Naguwa, S. M., Cheema, G. S., Shoenfeld, Y., & Gershwin, M. E. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.08.018 · Cited by 229
Prolonged remission in Caucasian patients with SLE: prevalence and outcomes
Zen, M., Iaccarino, L., Gatto, M., Bettio, S., Nalotto, L., Ghirardello, A., Punzi, L., & Doria, A. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207347 · Cited by 227
Guidelines on the use of extracorporeal photopheresis
Knobler, R., Berlin, G., Calzavara‐Pinton, P., Greinix, H., Jaksch, P., Laroche, L., Ludvigsson, J., Quaglino, P., Reinisch, W., Scarisbrick, J. J., et al. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12311 · Cited by 224
Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions
Ortega, L., Schultz, D., Lenz, O., Pardo, V., & Contreras, G. (2010) · Lupus · doi:10.1177/0961203309358187 · Cited by 219
Inflammatory markers in systemic lupus erythematosus
Aringer, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102374 · Cited by 229
European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative
Groot, N., de Graeff, N., Avčin, T., Bader‐Meunier, B., Brogan, P. A., Doležalová, P., Feldman, B. M., Koné‐Paut, I., Lahdenne, P., Marks, S. D., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210960 · Cited by 216
Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
Mahajan, A., Amelio, J., Gairy, K., Kaur, G., Levy, R. A., Roth, D. A., & Bass, D. (2020) · Lupus · doi:10.1177/0961203320932219 · Cited by 212
Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data‐driven review
Monach, P. A., Arnold, L. M., & Merkel, P. A. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25061 · Cited by 210
The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
Ünlü, O., Zuily, S., & Erkan, D. (2015) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2015.0085 · Cited by 212
Hydroxychloroquine retinopathy — implications of research advances for rheumatology care
Jorge, A. M., Ung, C., YOUNG, L. H. Y., Melles, R. B., & Choi, H. K. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0111-8 · Cited by 206
Pregnancy Outcomes in Patients with Autoimmune Diseases and Anti-Ro/SSA Antibodies
Brucato, A. L., Cimaz, R., Caporali, R. F., Ramoni, V. L., & Buyon, J. P. (2009) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-009-8190-6 · Cited by 201
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies
Sciascia, S., Hunt, B. J., Talavera-García, E., Lliso-Ribera, G., Khamashta, M. A., & Cuadrado, M. J. (2015) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.09.078 · Cited by 201
Antiphospholipid syndrome
Sammaritano, L. R. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.101463 · Cited by 211
S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)
Kuhn, A., Aberer, E., Bata‐Csörgõ, Z., Caproni, M., Dreher, A., Francès, C., Gläser, R., Klötgen, H., Landmann, A., Marinović, B., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14053 · Cited by 188
New therapeutic strategies in systemic lupus erythematosus management
Gatto, M., Zen, M., Iaccarino, L., & Doria, A. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0133-2 · Cited by 186
Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials
Petri, M., van Vollenhoven, R., Buyon, J. P., Levy, R. A., Navarra, S., Cervera, R., Zhong, Z. J., Freimuth, W. W., & Groups, O. B. O. T. B. A. B. S. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37995 · Cited by 181
Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus
Bortoluzzi, A., Scirè, C. A., Bombardieri, S., Caniatti, L. M., Conti, F., Vita, S. D., Doria, A., Ferraccioli, G., Gremese, E., Mansutti, E., et al. (2014) · Lara D. Veeken · doi:10.1093/rheumatology/keu384 · Cited by 172
Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus
Nossent, J. C., Kiss, E. V., Rozman, B., Pokorny, G., Vlachoyiannopoulos, P. G., Olesińska, M., Marchesoni, A., Mosca, M., Påi, S., Manger, K., et al. (2010) · Lupus · doi:10.1177/0961203310366572 · Cited by 169
First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)
Pons‐Estel, B. A., Bonfá, E., Soriano, E. R., Cardiel, M. H., Izcovich, A., Popoff, F., Criniti, J. M., Vásquez, G. M., Massardo, L., Duarte, M., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213512 · Cited by 165
The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus
Kraaij, T., Kamerling, S. W. A., de Rooij, E. N. M., van Daele, P. L. A., Bredewold, O. W., Bakker, J. A., Bajema, I. M., Scherer, H. U., Toes, R. E. M., Huizinga, T. W. J., et al. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.03.003 · Cited by 164
Belimumab: A Review in Systemic Lupus Erythematosus
Blair, H. A., & Duggan, S. T. (2018) · Drugs · doi:10.1007/s40265-018-0872-z · Cited by 161
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Perricone, C., Triggianese, P., Bartoloni, E., Cafaro, G., Bonifacio, A. F., Bursi, R., Perricone, R., & Gerli, R. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102468 · Cited by 158
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Merrill, J. T., Shanahan, W. R., Scheinberg, M. A., KALUNIAN, K. C., Wofsy, D., & Martin, R. S. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213032 · Cited by 157
Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines
Tunnicliffe, D. J., Singh‐Grewal, D., Kim, S., Craig, J. C., & Tong, A. (2015) · Arthritis Care & Research · doi:10.1002/acr.22591 · Cited by 154
Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade
Bertsias, G. K., Salmon, J. E., & Boumpas, D. T. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135186 · Cited by 152
Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes
González, L., Toloza, S., McGwin, G., & Alarcón, G. (2013) · Lupus · doi:10.1177/0961203313502571 · Cited by 154
European consensus statement on the terminology used in the management of lupus glomerulonephritis
Gordon, C., Jayne, D. R. W., Pusey, C. D., Adu, D., Amoura, Z., Aringer, M., Ballerin, J., Cervera, R., Alén, J. C., Chizzolini, C., et al. (2009) · Lupus · doi:10.1177/0961203308100481 · Cited by 150
Exercise and physical activity in systemic lupus erythematosus: A systematic review with meta-analyses
O’Dwyer, T., Durcan, L., & Wilson, F. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.04.003 · Cited by 151
Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs
Ruiz‐Irastorza, G., & Bertsias, G. K. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa403 · Cited by 148
Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos‐Casals, M., Hernández, F. J. G., de Ramón, E., Callejas-Rubio, J. L., Martínez-Berriotxoa, A., Pallarés, L., Caminal‐Montero, L., Selva-O’Callaghan, A., Oristrell, J., Hidalgo, C., et al. (2010) · PubMed · Cited by 140
The value of glucocorticoid co-therapy in different rheumatic diseases - positive and adverse effects
van der Goes, M. C., Jacobs, J. W. G., & Bijlsma, J. W. J. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4686 · Cited by 149
Optimizing outcome in SLE: treating-to-target and definition of treatment goals
Doria, A., Gatto, M., Zen, M., Iaccarino, L., & Punzi, L. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.055 · Cited by 138
Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR‐215757), a new quinoline‐3‐carboxamide derivative: Studies in lupus‐prone mice and a multicenter, randomized, double‐blind, placebo‐controlled, repeat‐dose, dose‐ranging study in patients with systemic lupus erythematosus
Bengtsson, A. A., Sturfelt, G. K., Lood, C., Rönnblom, L., van Vollenhoven, R., Axelsson, B., Sparre, B., Tuvesson, H., Öhman, M. W., & Leanderson, T. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33493 · Cited by 130
Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis
Ballocca, F., D’Ascenzo, F., Moretti, C., Omedè, P., Cerrato, E., Barbero, U., Abbate, A., Bertero, M. T., Biondi‐Zoccai, G., & Gaïta, F. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314546826 · Cited by 130
Gut Microbiome and Metabolites in Systemic Lupus Erythematosus: Link, Mechanisms and Intervention
Zhang, L., Qing, P., Yang, H., Wu, Y., Liu, Y., & Luo, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686501 · Cited by 132
Diagnosis and management of the antiphospholipid syndrome
Cohen, D. B., Berger, S. P., Steup‐Beekman, G. M., Bloemenkamp, K. W. M., & Bajema, I. M. (2010) · BMJ · doi:10.1136/bmj.c2541 · Cited by 127
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
Smolen, J. S., Schoels, M., Nishimoto, N., Breedveld, F. C., Burmester, G. R., Dougados, M., Emery, P., Ferraccioli, G., Gabay, C., Gibofsky, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202469 · Cited by 122
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life Setting
Gatto, M., Saccon, F., Zen, M., Regola, F., Fredi, M., Andréoli, L., Tincani, A., Urban, M. L., Emmi, G., Ceccarelli, F., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41253 · Cited by 123
Lupus: an overview of the disease and management options.
Maidhof, W., & Hilas, O. (2012) · PubMed Central · Cited by 116
Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis
Liu, D., Li, X., Zhang, Y., Kwong, J. S. W., Li, L., Zhang, Y., Xu, C., Li, Q., Sun, X., Tian, H., et al. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s166893 · Cited by 116
Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort
Kernder, A. L., Richter, J., Fischer‐Betz, R., Winkler-Rohlfing, B., Brinks, R., Aringer, M., Schneider, M., & Chehab, G. (2021) · Lupus · doi:10.1177/0961203320983445 · Cited by 121
Pragmatic approaches to therapy for systemic lupus erythematosus
Xiong, W., & Lahita, R. G. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.157 · Cited by 117
Systemic Lupus Erythematosus: A Review of the Disease and Treatment Options
Gurevitz, S. L., Snyder, J. A., Wessel, E. K., Frey, J., & Williamson, B. A. (2013) · The Consultant Pharmacist · doi:10.4140/tcp.n.2013.110 · Cited by 112
Treatment Algorithms in Systemic Lupus Erythematosus
Muangchan, C., van Vollenhoven, R., Bernatsky, S., Smith, C. D., Hudson, M., İnanç, M., Rothfield, N. F., Nash, P. T., Furie, R. A., Senécal, J., et al. (2015) · Arthritis Care & Research · doi:10.1002/acr.22589 · Cited by 109
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Fasano, S., Pierro, L., Pantano, I., Iudici, M., & Valentini, G. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161351 · Cited by 111
Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome
Bellver, J., & Pellicer, A. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.06.033 · Cited by 110
Systemic lupus erythematosus: state of the art on clinical practice guidelines
Tamirou, F., Arnaud, L., Talarico, R., Scirè, C. A., Alexander, T., Amoura, Z., Avčin, T., Bortoluzzi, A., Cervera, R., Conti, F., et al. (2018) · RMD Open · doi:10.1136/rmdopen-2018-000793 · Cited by 104
Lupus arthritis--do we have a clinically useful classification?
Ball, E., & Bell, A. L. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker381 · Cited by 102
Association between chronic immune-mediated inflammatory diseases and cardiovascular risk
Baena-Díez, J. M., García-Gil, M., Comas‐Cufí, M., Ramos, R., Prieto‐Alhambra, D., Salvador-González, B., Elosúa, R., Degano, I. R., Peñafiel, J., & Grau, M. (2017) · Heart · doi:10.1136/heartjnl-2017-311279 · Cited by 102
Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review
ACRONIM, O. B. O. T. F., Gensous, N., Marti, A., Barnetche, T., Blanco, P., Lazaro, E., Sénéschal, J., Truchetet, M., Duffau, P., & Richez, C. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1442-6 · Cited by 99
Pregnancy Outcomes and Appropriate Timing of Pregnancy in 183 pregnancies in Korean Patients with SLE
Ko, H. S., Ahn, H. Y., Jang, D. G., Choi, S. K., Park, Y. G., Park, I. Y., Lee, G., Park, S., & Shin, J. C. (2011) · International Journal of Medical Sciences · doi:10.7150/ijms.8.577 · Cited by 97
The treatment strategies of autoimmune disease may need a different approach from conventional protocol: A review
Chandrashekara, S. (2012) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.103235 · Cited by 91
Cumulative Burden of Glucocorticoid-related Adverse Events in Patients with Systemic Lupus Erythematosus: Findings from a 12-year Longitudinal Study
Chen, H.-L., Shen, L., Hsu, P., Shen, C., Hall, S. A., & Hsiao, F. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.160214 · Cited by 99
Glucocorticoids
Spies, C. M., Strehl, C., van der Goes, M. C., Bijlsma, J. W. J., & Buttgereit, F. (2011) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2011.11.002 · Cited by 108
Audiovestibular Symptoms in Systemic Autoimmune Diseases
Ralli, M., D’Aguanno, V., Stadio, A. D., VIRGILIO, A. D., Croce, A., Longo, L., Greco, A., & VINCENTIIS, M. D. (2018) · Journal of Immunology Research · doi:10.1155/2018/5798103 · Cited by 92
Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
Castrejón, I., Tani, C., Jolly, M., Huang, A., & Mosca, M. (2014) · PubMed · Cited by 89
Association between vitamin D receptor ( VDR ) gene polymorphisms and systemic lupus erythematosus in Portuguese patients
Carvalho, C., Marinho, A., Leal, B., Bettencourt, A., Boleixa, D., Almeida, I., Farinha, F., Costa, P., Vasconcelos, C., & da Silva, B. M. (2015) · Lupus · doi:10.1177/0961203314566636 · Cited by 88
An update on diet and nutritional factors in systemic lupus erythematosus management
Aparicio‐Soto, M., Sánchéz‐Hidalgo, M., & Alarcón‐de‐la‐Lastra, C. (2017) · Nutrition Research Reviews · doi:10.1017/s0954422417000026 · Cited by 89
Human Cytomegalovirus and Autoimmune Diseases: Where Are We?
Gugliesi, F., Pasquero, S., Griffante, G., Scutera, S., Albano, C., Pacheco, S. F. C., Riva, G., Dell’Oste, V., & Biolatti, M. (2021) · Viruses · doi:10.3390/v13020260 · Cited by 87
Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis
Lü, X., Wang, Y., Zhang, J., Pu, D., Hu, N., Luo, J., An, Q., & He, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107466 · Cited by 98
Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers
Efthimiou, P., & Blanco, M. (2009) · Modern Rheumatology · doi:10.1007/s10165-009-0198-5 · Cited by 88
Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares
Matrat, A., Veysseyre-Balter, C., Trolliet, P., Villar, E., Dijoud, F., Bienvenu, J., & Fabien, N. (2010) · Lupus · doi:10.1177/0961203310379871 · Cited by 86
Vitamin D Endocrine System and the Immune Response in Rheumatic Diseases
Cutolo, M., Plebani, M., Shoenfeld, Y., Adorini, L., & Tincani, A. (2011) · Vitamins & Hormones · doi:10.1016/b978-0-12-386960-9.00014-9 · Cited by 86
A randomized double-blind placebo-controlled study adding high dose vitamin D to analgesic regimens in patients with musculoskeletal pain
Gendelman, O., Itzhaki, D., Makarov, S., Bennun, M., & Amital, H. (2015) · Lupus · doi:10.1177/0961203314558676 · Cited by 85
How I treat the antiphospholipid syndrome
Giannakopoulos, B., & Krilis, S. A. (2009) · Blood · doi:10.1182/blood-2009-05-220756 · Cited by 83
Annual direct medical cost of active systemic lupus erythematosus in five European countries
Doria, A., Amoura, Z., Cervera, R., Khamastha, M., Schneider, M., Richter, J., Guillemin, F., Kobelt, G., Maurel, F., Garofano, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202443 · Cited by 84
First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study
Schwarting, A., Schroeder, J. O., Alexander, T., Schmalzing, M., Fiehn, C., Specker, C., Perna, A., Cholmakow-Bodechtel, C., Koscielny, V., & Carnarius, H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0047-x · Cited by 84
Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus?
Dima, A., Opriș-Belinski, D., Jurcuț, C., & Băicuş, C. (2016) · Lupus · doi:10.1177/0961203316651742 · Cited by 82
Efficacy and safety of infliximab in active SLE: a pilot study
Uppal, S., Hayat, S. H. M., & Raghupathy, R. (2009) · Lupus · doi:10.1177/0961203309102557 · Cited by 80
Current state of evidence on ‘off-label’ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland – a consensus report
Aringer, M., Burkhardt, H., Burmester, G. R., Fischer‐Betz, R., Fleck, M., Graninger, W. B., Hiepe, F., Jacobi, A., Kötter, I., Lakomek, H. J., et al. (2011) · Lupus · doi:10.1177/0961203311426569 · Cited by 79
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
Furie, R. A., Petri, M., Strand, V., Gladman, D. D., Zhong, Z. J., Freimuth, W. W., & Groups, T. B.-5. A. B.-7. S. (2014) · Lupus Science & Medicine · doi:10.1136/lupus-2014-000031 · Cited by 78
A structured literature review of the direct costs of adult systemic lupus erythematosus in the US
Slawsky, K. A., Fernandes, A. W., Fusfeld, L., Manzi, S., & Goss, T. F. (2011) · Arthritis Care & Research · doi:10.1002/acr.20502 · Cited by 78

Authors: Bertsias, G., Ioannidis, J. P. A., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., Font, J., Gilboe, I. M., Houssiau, F., Huizinga, T., Isenberg, D., Kallenberg, C. G. M., Khamashta, M., Piette, J. C., Schneider, M., Smolen, J., Sturfelt, G., Tincani, A., van Vollenhoven, R., Gordon, C., & Boumpas, D. T.
Affiliations: University of Crete (GR)
University of Ioannina (GR)
Laiko General Hospital of Athens (GR)
University of Pisa (IT)
Hospital Clínic de Barcelona (ES)
Oslo University Hospital (NO)
Cliniques Universitaires Saint-Luc (BE)
Leiden University Medical Center (NL)
University College Hospital (GB)
University Medical Center Groningen (NL)
St Thomas' Hospital (GB)
Heinrich Heine University Düsseldorf (DE)
Medical University of Vienna (AT)
Lund University (SE)
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
University of Birmingham (GB)
Corresponding author: Boumpas, D T
ORCID: Bertsias, G
Ioannidis, J P A
Bombardieri, S
Cervera, R
Huizinga, T
Isenberg, D
Khamashta, M
Schneider, M
Smolen, J
Tincani, A
Gordon, C
Boumpas, D T
Venue: Annals of the Rheumatic Diseases
Publisher: Elsevier BV
Published: 2008-02
Volume: 67
Issue: 2
Pages: 195-205
ISSN: 0003-4967 (ISSN-L)
DOI: 10.1136/ard.2007.070367
OpenAlex: W2157038471
Cited by: 762
References: 164
Citations by year: 2026: 14 · 2025: 17 · 2024: 19 · 2023: 26 · 2022: 19 · 2021: 58 · 2020: 56 · 2019: 53 · 2018: 70 · 2017: 62 · 2016: 47 · 2015: 53 · 2014: 43 · 2013: 53 · 2012: 46
FWCI: 18.49
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor)
Locations: Annals of the Rheumatic Diseases (publishedVersion)
PubMed (publishedVersion)
Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
Lund University Publications (Lund University) (submittedVersion)
HighWire Press Open Archive (submittedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders: University of Crete
Topics: Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
Keywords: systemic lupus erythematosus, clinical management, diagnosis, prognosis, disease surveillance, treatment, neuropsychiatric lupus, pregnancy, antiphospholipid syndrome, lupus nephritis, evidence-based recommendations, expert consensus
MeSH terms: Female, Humans, Lupus Erythematosus, Systemic, Lupus Nephritis, Male, Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks